Maruti Suzuki Q3 PAT rises 12.6% to ₹3,525 crore, board approves merger of Gujarat unit with MSIL


Maruti Suzuki India Ltd., (MSIL), India’s biggest passenger car company, for the third quarter ended December 31, 2024 reported a 12.6% growth in net profit to ₹3,525 crore.

The margin improvement is attributed to favourable operating leverage and higher non-operating income. The company during the quarter it had incurred higher sales promotional expense, possibly to beat the down trend. The company did not specify the amount spent.

During the quarter, the company registered net sales income of ₹36,802 crore against ₹31,860 crore in the same period last year, up 15.5%. 

For the period under review the company sold a total of 5,66,213 vehicles as compared with 5,01,207 units sold in the same period last year, up 13%. 

This included domestic market sales of 466,993 units, up 18.7% Year on Year (YoY). The company during the quarter exported 99,220 units, up 38.2% YoY. 

Segment wise the company’s mini segment cars saw 2.8% growth in sales at 27,855 units, the compact segment witnessed de-growth of 4.6% to 1,82,227 units, the mid- size segment grew 17.6 to 1,720 units. 

While the Utility Vehicles (UV) segment grew 20.2% to 1,85,298 units, the vans segment grew 2.1% to 33,920 units, the Light Commercial Vehicles (LCV) segment grew 9.3% to 8,871 units.

Sales to other OEMs, specifically to Toyota Kirloskar Motor, during the quarter grew 89% to 27,102 units.

The company’s Board on Wednesday approved a scheme of amalgamation of Suzuki Motor Gujarat Private Ltd (SMGPL), a wholly owned subsidiary, with MSIL. 

The scheme is subject to the receipt of approval from the requisite majorities of shareholders and creditors of SMG and MSIL and approvals from respective National Company Law Tribunals. 

On October, 29, 2024 the company had intimated that its board of directors had granted its in-principle approval for amalgamation.



Source link

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *